Literature DB >> 7506417

A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression.

J Jouanneau1, G Moens, Y Bourgeois, M F Poupon, J P Thiery.   

Abstract

It is generally accepted that primary tumors become heterogeneous as a consequence of tumor-cell genetic instability. Clonal dominance has been shown to occur in some experimental models allowing a subpopulation of cells to overgrow the primary heterogeneous tumor and to metastasize. Alternatively, interactions among coexisting tumor subpopulations may contribute to the emergence of a malignant invasive primary solid tumor. We asked the question whether emergence of carcinoma cells producing a growth/dissociating factor within a tumor cell population may be a determinant for tumor progression and for clonal dominance. To mimic such a situation, we have investigated the impact of tumor subpopulation heterogeneity in an in vivo model in which mixtures of carcinoma cells that differ in their ability to produce acidic fibroblast growth factor are injected into nude mice. Our data indicate that a growth-factor-producing cell subpopulation can confer increased tumorigenicity to an entire cell population and subsequently elicit a shorter delay for appearance of metastasis. A community effect via cell interactions may account for a heterogeneous tumor cell population rather than clonal dominance during progression of certain tumor types.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506417      PMCID: PMC42932          DOI: 10.1073/pnas.91.1.286

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Basic fibroblast growth factor induces angiogenesis in vitro.

Authors:  R Montesano; J D Vassalli; A Baird; R Guillemin; L Orci
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 2.  Modes of FGF release in vivo and in vitro.

Authors:  P A D'Amore
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

Review 3.  Growth dominance of the metastatic cancer cell: cellular and molecular aspects.

Authors:  R S Kerbel
Journal:  Adv Cancer Res       Date:  1990       Impact factor: 6.242

4.  Mesenchymal-epithelial interactions between normal and transformed human bladder cells.

Authors:  T R Pritchett; J K Wang; P A Jones
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

5.  A new dominant hybrid selective marker for higher eukaryotic cells.

Authors:  F Colbère-Garapin; F Horodniceanu; P Kourilsky; A C Garapin
Journal:  J Mol Biol       Date:  1981-07-25       Impact factor: 5.469

Review 6.  Tumor heterogeneity.

Authors:  G H Heppner
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

7.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.

Authors:  D R Welch; A Fabra; M Nakajima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 8.  Cellular interactions in metastasis.

Authors:  F R Miller; G H Heppner
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

9.  Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells.

Authors:  S C Chen; C K Chou; F H Wong; C M Chang; C P Hu
Journal:  Cancer Res       Date:  1991-04-01       Impact factor: 12.701

10.  Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line.

Authors:  A M Vallés; B Boyer; J Badet; G C Tucker; D Barritault; J P Thiery
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

View more
  16 in total

1.  Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis.

Authors:  J Rak; Y Mitsuhashi; C Sheehan; J K Krestow; V A Florenes; J Filmus; R S Kerbel
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

2.  Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer.

Authors:  Marco Archetti; Daniela A Ferraro; Gerhard Christofori
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

Review 3.  The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells.

Authors:  M Zanetti; J J Rodvold; N R Mahadevan
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

Review 4.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

5.  Co-inoculation of human and murine carcinoma cells induces reciprocal suppression of metastasis by both cell lines.

Authors:  S M Nielsen-Preiss; J P Quigley; J E Testa
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

6.  Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization.

Authors:  J C Rockett; K Larkin; S J Darnton; A G Morris; H R Matthews
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  IL-18 regulates melanoma VLA-4 integrin activation through a Hierarchized sequence of inflammatory factors.

Authors:  María Valcárcel; Teresa Carrascal; Olatz Crende; Fernando Vidal-Vanaclocha
Journal:  J Invest Dermatol       Date:  2013-08-12       Impact factor: 8.551

8.  Insidious communication amongst cancer cells.

Authors:  Jeffrey J Rodvold; Maurizio Zanetti
Journal:  Mol Cell Oncol       Date:  2018-04-19

9.  The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy.

Authors:  Yousef H Aldebasi; Arshad H Rahmani; Amjad A Khan; Salah Mesalhy Aly
Journal:  Int J Clin Exp Med       Date:  2013-04-12

10.  Dynamics of growth factor production in monolayers of cancer cells and evolution of resistance to anticancer therapies.

Authors:  Marco Archetti
Journal:  Evol Appl       Date:  2013-08-15       Impact factor: 5.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.